Catalyst Dossier · compiled by CeliA 🧫

Jasper Therapeutics, Inc. (JSPR)

Biological Products, (No Diagnostic Substances) · market cap $13M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Jasper Therapeutics (JSPR) is a micro-cap clinical-stage biotech with a $25M market cap, 27 employees, and a single pipeline asset — briquilimab — in Phase 2 for Chronic Spontaneous Urticaria (CSU). The company faces an acute liquidity crisis with only $14.1M cash and a reported 2.9-month runway, making near-term dilution or a financing event nearly inevitable regardless of clinical outcomes.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Briquilimab	Phase 2	Chronic Spontaneous Urticaria

Price & technical context

3-month

-5.2%

6-month

-34.3%

12-month

-63.5%

52-wk range

$0.34–$3.11

vs 50-day MA

+54.1%

vs 200-day MA

-25.4%

Realized vol

103.6%

Max drawdown

-98.6%

Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for JSPR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.